SAB BIOTHERAPEUTICS, INC. Acquisition Costs, Period Cost
SAB BIOTHERAPEUTICS, INC. (SABS) reported Acquisition Costs, Period Cost of $5.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AcquisitionCosts · last filed 2024-05-20
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2024-03-31 was $5.00K, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2023-06-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2023-03-31 was $5.00K, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for the quarter ending 2022-12-31 was $0.00.
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for fiscal 2023 was $5.00K, a 0.00% change from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for fiscal 2022 was $5.00K, a 0.00% change from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. acquisition costs, period cost for fiscal 2021 was $5.00K.
| Period end | Acquisition Costs, Period Cost 3 month | Acquisition Costs, Period Cost 6 month | Acquisition Costs, Period Cost 9 month | Acquisition Costs, Period Cost 12 month |
|---|---|---|---|---|
| 2024-03-31 | $5.00K 10-Q · filed 2024-05-20 | |||
| 2023-12-31 | $5.00K 10-K · filed 2024-03-29 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $5.00K 10-Q · filed 2023-08-21 | $5.00K derived: sum of 3 quarters · filed 2023-08-21 | $5.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $5.00K 10-Q · filed 2023-05-15 | $5.00K derived: sum of 2 quarters · filed 2023-05-15 | $5.00K derived: sum of 3 quarters · filed 2023-11-13 | $5.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 derived: sum of 3 quarters · filed 2023-11-13 | $5.00K 10-K · filed 2023-04-14 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $5.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $5.00K 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $5.00K 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $5.00K 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |